Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same author

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
Same author

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same author

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

European urology oncology·2026
Same author

Comment to: "Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type".

World journal of urology·2026

Related Experiment Video

Updated: Apr 20, 2026

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement
09:50

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement

Published on: October 1, 2014

11.9K

EAU guidelines on penile cancer: 2014 update.

Oliver W Hakenberg1, Eva M Compérat2, Suks Minhas3

  • 1Department of Urology, University Hospital Rostock, Rostock, Germany.

European Urology
|December 3, 2014
PubMed
Summary

Organ-preserving treatments are now standard for low-stage penile cancer. Multimodal therapy, including surgery and chemotherapy, improves outcomes for advanced lymphatic disease.

Keywords:
ChemotherapyEuropean Association of UrologyFollow-upGuidelinesInvasive diseaseLaserLymph nodeMetastasisPenile cancerQuality of lifeReconstructionSquamous cell carcinomaSurgery

More Related Videos

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

3.1K
A 3D Spheroid Model for Glioblastoma
07:40

A 3D Spheroid Model for Glioblastoma

Published on: April 9, 2020

16.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement
09:50

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement

Published on: October 1, 2014

11.9K
Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

3.1K
A 3D Spheroid Model for Glioblastoma
07:40

A 3D Spheroid Model for Glioblastoma

Published on: April 9, 2020

16.6K

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Penile cancer carries a high mortality rate upon metastasis.
  • Current local treatments can be disfiguring, necessitating advancements in organ-preserving options.
  • Updates to European Association of Urology guidelines are required due to progress in treatment.

Purpose of the Study:

  • To provide an evidence-based update of penile cancer treatment recommendations.
  • To review literature published between August 2008 and November 2013.
  • To inform updated European Association of Urology guidelines.

Main Methods:

  • A comprehensive PubMed search was conducted for literature from August 2008 to November 2013.
  • 352 full-text papers were systematically reviewed.
  • Evidence levels and recommendation grades were assessed, noting limitations due to a lack of controlled trials.

Main Results:

  • Penile squamous cell carcinoma has HPV-related and unrelated histologic variants.
  • Organ-preserving local treatment is recommended for primary penile cancer, with no outcome differences for superficial and T1 disease.
  • Inguinal lymph node management is critical; invasive staging is advised for impalpable nodes based on risk factors. N2/N3 disease requires surgery and adjuvant chemotherapy.

Conclusions:

  • Organ preservation is the standard for early-stage penile cancer.
  • Multimodal treatment, including radical inguinal node surgery and adjuvant chemotherapy, enhances outcomes in lymphatic penile cancer.
  • Approximately 80% of penile cancer patients can be cured with appropriate management.